Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: Final results and long-term outcome

Journal of Clinical Oncology

Volumn 31, Issue 31, 2013, Pages 3971-3979

  Morris, Patrick G ^a   Correa, Denise D ^a   Yahalom, Joachim ^a   Raizer, Jeffrey J ^c   Schiff, David ^d   Grant, Barbara ^e   Grimm, Sean ^c   Lai, Rose K ^b   Reiner, Anne S ^a   Panageas, Kathy ^a   Karimi, Sasan ^a   Curry, Richard ^a   Shah, Gaurav ^a   Abrey, Lauren E ^a   DeAngelis, Lisa M ^a   Omuro, Antonio ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Columbia University ^*  (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

^e UNIVERSITY OF VERMONT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; METHOTREXATE; PROCARBAZINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; DRUG EFFICACY; EXECUTIVE FUNCTION; FEMALE; FOLLOW UP; HUMAN; KARNOFSKY PERFORMANCE STATUS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT OUTCOME; TREATMENT RESPONSE; VERBAL MEMORY; WHITE MATTER; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHEMORADIOTHERAPY; CLINICAL TRIAL; DISEASE FREE SURVIVAL; LYMPHOMA; MORTALITY; SKULL IRRADIATION; TIME; CENTRAL NERVOUS SYSTEM TUMOR; METHODOLOGY;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHEMORADIOTHERAPY; CRANIAL IRRADIATION; CYTARABINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHOMA; MALE; METHOTREXATE; MIDDLE AGED; PROCARBAZINE; TIME; TREATMENT OUTCOME; VINCRISTINE;

EID: 84891609260     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.50.4910     Document Type: Article

References (46)

1. Morris PG, Abrey LE: Therapeutic challenges in primary CNS lymphoma. Lancet Neurol 8:581-592, 2009
2. Ferreri AJ, DeAngelis L, Illerhaus G, et al: Whole-brain radiotherapy in primary CNS lymphoma. Lancet Oncol 12:118-119, 2011
3. Korfel A, Thiel E, Martus P, et al: Whole-brain radiotherapy in primary CNS lymphoma (authors' reply). Lancet Oncol 12:119-120, 2011
4. Graber JJ, Omuro A: Primary central nervous system lymphoma: Is there still a role for radiotherapy? Curr Opin Neurol 24:633-640, 2011
5. Thiel E, Korfel A, Martus P, et al: High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): A phase 3, randomised, non-inferiority trial. Lancet Oncol 11:1036-1047, 2010
6. Omuro A, Taillandier L, Chinot O, et al: Primary CNS lymphoma in patients younger than 60: Can whole-brain radiotherapy be deferred? J Neurooncol 104:323-330, 2011
7. Batchelor T, Carson K, O'Neill A, et al: Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: A report of NABTT 96-07. J Clin Oncol 21:1044-1049, 2003 (Pubitemid 46594133)
8. Pels H, Schmidt-Wolf IG, Glasmacher A, et al: Primary central nervous system lymphoma: Results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol 21:4489-4495, 2003 (Pubitemid 46594018)
9. Abrey LE, Yahalom J, DeAngelis LM: Treatment for primary CNS lymphoma: The next step. J Clin Oncol 18:3144-3150, 2000
10. Abrey LE, DeAngelis LM, Yahalom J: Longterm survival in primary CNS lymphoma. J Clin Oncol 16:859-863, 1998 (Pubitemid 28108717)
11. Omuro AM, Ben-Porat LS, Panageas KS, et al: Delayed neurotoxicity in primary central nervous system lymphoma. Arch Neurol 62:1595-1600, 2005 (Pubitemid 41434567)
12. Ferreri AJ, Reni M, Pasini F, et al: A multicenter study of treatment of primary CNS lymphoma. Neurology 58:1513-1520, 2002 (Pubitemid 34552959)
13. Ekenel M, Iwamoto FM, Ben-Porat LS, et al: Primary central nervous system lymphoma: The role of consolidation treatment after a complete re-sponseto-high-dosemethotrexate-basedchemotherapy. Cancer 113:1025-1031, 2008
14. Gavrilovic IT, Hormigo A, Yahalom J, et al: Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol 24:4570-4574, 2006 (Pubitemid 46630953)
15. Coiffier B, Lepage E, Briere J, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242, 2002 (Pubitemid 34438862)
16. Shah GD, Yahalom J, Correa DD, et al: Combined immunochemotherapy with reduced wholebrain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol 25:4730-4735, 2007 (Pubitemid 350086474)
17. Abrey LE, Batchelor TT, Ferreri AJ, et al: Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 23:5034-5043, 2005 (Pubitemid 46224010)
18. Correa DD, DeAngelis LM, Shi W, et al: Cognitive functions in survivors of primary central nervous system lymphoma. Neurology 62:548-555, 2004 (Pubitemid 38252794)
19. Correa DD, Maron L, Harder H, et al: Cognitive functions in primary central nervous system lymphoma: Literature review and assessment guidelines. Ann Oncol 18:1145-1151, 2007 (Pubitemid 47244358)
20. Correa DD, Rocco-Donovan M, Deangelis LM, et al: Prospective cognitive follow-up in primary CNS lymphoma patients treated with chemotherapy and reduced-dose radiotherapy. J Neurooncol 91:315-321, 2009
21. Fazekas F, Chawluk JB, Alavi A, et al: MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJR Am J Roentgenol 149: 351-356, 1987 (Pubitemid 17104996)
22. Correa DD, Shi W, Abrey LE, et al: Cognitive functions in primary CNS lymphoma after single or combined modality regimens. Neuro Oncol 14:101-108, 2012
23. Corn BW, Yousem DM, Scott CB, et al: White matter changes are correlated significantly with radiation dose: Observations from a randomized dose-escalation trial for malignant glioma (Radiation Therapy Oncology Group 83-02). Cancer 74:2828-2835, 1994 (Pubitemid 24340551)
24. Barajas RF Jr, Rubenstein JL, Chang JS, et al: Diffusion-weighted MR imaging derived apparent diffusion coefficient is predictive of clinical outcome in primary central nervous system lymphoma. AJNR Am J Neuroradiol 31:60-66, 2010
25. Abrey LE, Ben-Porat L, Panageas KS, et al: Primary central nervous system lymphoma: The Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol 24:5711-5715, 2006 (Pubitemid 46631313)
26. Morris PG, Abrey LE, Reiner AS, et al: Methotrexate area under the curve as a prognostic factor in primary central nervous system lymphoma treated with immunochemoradiotherapy. Leuk Lymphoma 52:1891-1897, 2011
27. DeAngelis LM, Yahalom J, Thaler HT, et al: Combined modality therapy for primary CNS lymphoma. J Clin Oncol 10:635-643, 1992
28. Glass J, Gruber ML, Cher L, et al: Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: Long-term outcome. J Neurosurg 81:188-195, 1994 (Pubitemid 24237996)
29. DeAngelis LM, Seiferheld W, Schold SC, et al: Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol 20:4643-4648, 2002 (Pubitemid 36025280)
30. Bessell EM, López-Guillermo A, Villá S, et al: Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: An analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments. J Clin Oncol 20:231-236, 2002 (Pubitemid 34032616)
31. Poortmans PM, Kluin-Nelemans HC, Haaxma- Reiche H, et al: High-dose methotrexate-basedchemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. J Clin Oncol 21:4483-4488, 2003 (Pubitemid 46594017)
32. Omuro AM, DeAngelis LM, Yahalom J, et al: Chemoradiotherapy for primary CNS lymphoma: An intent-to-treat analysis with complete follow-up. Neurology 64:69-74, 2005 (Pubitemid 40082939)
33. Korfel A, Martus P, Nowrousian MR, et al: Response to chemotherapy and treating institution predict survival in primary central nervous system lymphoma. Br J Haematol 128:177-183, 2005
34. Ferreri AJ, Dell'Oro S, Foppoli M, et al: MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas. Neurology 66:1435-1438, 2006 (Pubitemid 43739659)
35. Ferreri AJ, Reni M, Foppoli M, et al: High-dose cytarabine plus high-dose methotrexate versus highdose methotrexate alone in patients with primary CNS lymphoma: A randomised phase 2 trial. Lancet 374:1512-1520, 2009
36. Herrlinger U, Schabet M, Brugger W, et al: German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma. Ann Neurol 51:247-252, 2002 (Pubitemid 34111448)
37. Pels H, Juergens A, Glasmacher A, et al: Early relapses in primary CNS lymphoma after response to polychemotherapy without intraventricular treatment: Results of a phase II study. J Neurooncol 91:299-305, 2009
38. Wieduwilt MJ, Valles F, Issa S, et al: Immunochemotherapy with intensive consolidation for primary CNS lymphoma: A pilot study and prognostic assessment by diffusion-weighted MRI. Clin Cancer Res 18:1146-1155, 2012
39. Hoang-Xuan K, Taillandier L, Chinot O, et al: Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: A multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. J Clin Oncol 21:2726-2731, 2003 (Pubitemid 46606318)
40. Omuro AM, Taillandier L, Chinot O, et al: Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly. J Neurooncol 85:207-211, 2007 (Pubitemid 47629402)
41. Gerstner ER, Zhu JJ, Engler DA, et al: High dose methotrexate for elderly patients with primary central nervous system lymphoma. Neuro Oncol 11:211-215, 2008
42. Fritsch K, Kasenda B, Hader C, et al: Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly. Ann Oncol 22:2080-2085, 2011
43. Batchelor TT, Grossman SA, Mikkelsen T, et al: Rituximab monotherapy for patients with recurrent primary CNS lymphoma. Neurology 76:929-930, 2011
44. Omuro AM, Martin-Duverneuil N, Delattre JY: Complications of radiotherapy to the central nervous system. Handb Clin Neurol 105:887-901, 2012
45. Soussain C, Hoang-Xuan K, Taillandier L, et al: Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Societe Francaise de Greffe de Moelle Osseuse-Therapie Cellulaire. J Clin Oncol 26:2512-2518, 2008
46. Illerhaus G, Marks R, Ihorst G, et al: High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as firstline treatment of primary CNS lymphoma. J Clin Oncol 24:3865-3870, 2006 (Pubitemid 46630733)